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A twelve year natural history of hepatitis C virus infection in hemodia-
lyzed patients. A prospective non-A, non-B follow-up program, imple-
mented in a hepatitis B surface antigen-free dialysis unit, enabled us to
report on the natural history of hepatitis C virus (HCV) infection in
hemodialyzed patients between 1980 and 1992. For this program, every
patient was prospectively monitored every two weeks for alanine amino
transferase (ALT) activity, and every month for gammaglutamyl transpep-
tidase (GGT) activity and systematic collection of frozen sera. Sequences
of stored sera from 217 patients were repeatedly tested for anti-HCV
antibodies using second generation assays. Eighty-six of the 217 patients
(39.6%), including 61 of the 67 patients with non-A, non-B hepatitis
(91%), had HCV infection repeatedly evidenced by positive ELISA in all,
and confirmed by RIBA in 84 of 86 (97.5%). In addition, 19 out of 23
patients (82.6%) were positive for HCV RNA by the polymerase chain
reaction (PCR). Of the 86 anti-HCV positive patients, 41 had previously
acquired HCV infection, and 45 seroconverted during chronic dialysis. Of
these, all but one patient developed hepatitis with raised ALT activity
which lasted for at least six months in all. Only 29 of 45 patients (64.5%)
had a history of blood transfusion. Seventy-eight of the 86 patients (91%)
who were followed up for one to 11.5 years (median 5) retained anti-HCV
for several years. Nineteen liver biopsies performed in 16 patients showed
chronic active hepatitis in 8 (50%) and hepatocellular carcinoma without
cirrhosis in one patient. In most cases, the outcome of HCV infection was
chronic, since 54 patients (69.2%) exhibited persistently elevated GGT
and anti-HCV positivity combined with either abnormal or fluctuating
ALT (30.8%) or normal ALT (38.4%), and 16 patients (20.5%) had
persistently elevated anti-HCV titers. Resolutive hepatitis C was uncom-
mon since only eight patients (10.3%) gradually lost their HCV markers.
The incidence and cumulative risk of seroconversion only decreased after
1988 to 1990, when routine testing of the blood supply for surrogate
markers and anti-HCV antibody was started in France. The incidence of
post-transfusion hepatitis became nil in 1990 before that of nosocomial
infection (1991). HCV prevalence also decreased, from 43.6 to 29.2%. In
conclusion, HCV was responsible for 91% of non-A, non-B hepatitis cases.
Hepatitis was identified as the primary HCV infection in all but one case.
GGT activity emerged as a reliable marker of long-term HCV infection.
The severity of the disease seems to correlate with the persistence of ALT
and/or GGT changes, combined with that of anti-HCV and HCV RNA
positivity. Transmission of HCV was both transfusional and nosocomial.
HCV prophylaxis should now focus on the eradication of nosocomial
infection.
After the identification of hepatitis C virus (HCV) as the major
agent responsible for transfusion-associated non-A, non-B hepa-
titis [1—31, one of the important achievements resulting from the
progress made in characterizing the HCV genome [4] was the
introduction of second generation assays for the detection of
antibodies to HCV, which clearly improved the identification of
hepatitis C [5].
This 12-year follow-up study of HCV infection is a secondary
benefit from the program of prophylaxis against hepatitis B virus
(HBV) implemented since the creation of our hospital's dialysis
department. As soon as the program was enforced, this prophy-
laxis, which has proven effective from 1978 until now, facilitated
the identification of non-A, non-B hepatitis. We therefore tracked
down this new form of hepatitis, and since 1980 an individualized
bank of frozen sera has been stored for all patients at monthly
intervals. This serological material was immediately used for the
preliminary anti-HCV testing in 1980 [6], and then for the
improved anti-HCV assays which became available in 1989. We
report here the results of this long-term follow-up study, which is
both prospective and retrospective, and focuses on the clinical and
epidemiologic aspects of HCV infection in a single dialysis unit.
Methods
Since January 1, 1978, all patients admitted to our new pilot
dialysis department, at the Centre Hospitalier Pasteur-Vallery-
Radot in Paris, AURA, France, have been enrolled in a prospec-
tive and preventive follow-up program against HBV infection in
hemodialyzed patients. This program, based on the selection of
patients negative for hepatitis B surface antigen (HBs Ag) and on
the prospective follow-up of HBV serology, was soon combined
with a program for the prospective detection of non-A, non-B
hepatitis. To classify this recently identified hepatitis of undefined
cause, particularly in hemodialyzed patients, we created, in 1980,
an individualized bank of frozen sera prospectively stored at
intervals of at least one month. We then waited until reliable HCV
assays became available. We report here on the different clinical
and epidemiologic patterns of HCV infection identified in our
dialysis unit by this prospective program over a period of up to 12
years.
Enrollment and follow-up program
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For the purpose of this study, carried out between January 1,
1980 and January 1, 1992, we selected 217 consecutive hemodia-
lyzed patients who had been dialyzed in our facility for at least one
whole year (range: ito 14 years). When anti-HCV testing became
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available, all these patients were tested for anti-HCV antibodies
at yearly intervals for at least two consecutive years. The 217
patients included 124 who started dialysis in our unit, and 93 who
had been previously dialyzed in other units. The follow-up pro-
gram for each patient comprized measurements of serum alanine
aminotransferase (ALT) and aspartate aminotransferase activity
twice a month, and of alkaline phosphatase and gamma glutamyl
transpeptidase (GGT) activity once a month. Whenever hepatitis
was suspected, the interval between these measurements was
shortened to a week for a month. In addition, sequences of frozen
sera were collected and stored upon entry into the dialysis facility
and subsequently at monthly intervals. Whenever biochemical
hepatitis was suspected, the interval of collection was also short-
ened to a week for a month. Therefore, each patient completed an
individualized clinical and serological follow-up which began at
admission and stopped at one of the four end points: death,
transplantation, transfer to another unit or the end of the period
studied.
Non-A, non-B hepatitis was suspected if ALT activity rose to
twice the upper limit of normal on at least one occasion and
displayed another abnormal value in two consecutive measure-
ments separated by a period of 5 to 17 days. It was diagnosed in
the absence of other clinical causes of liver disease. Interviews and
review of medical records excluded patients with recent infection
by hepatitis B or A virus or reactivation of cytomegalovirus,
herpes virus and Epstein-Barr virus. Hepatitis was defined as
icteric on the basis of clinical jaundice, and as subicteric if the
bilirubin level was above the upper normal limit without icterus.
The course of hepatitis was considered chronic if abnormal or
fluctuating ALT activity lasted six months or more. The infection
was attributed to HCV after anti-HCV antibodies had been
retrospectively tested in every patient from the beginning until the
end of follow-up. The severity of the disease was assessed on the
following laboratory tests, performed at least once a year: 5'nu-
cleotidase activity, bilirubin level, prothrombin time, total protein,
protein electrophoresis, albumin, iron and serum ferritin levels,
and antinuclear antibody testing. Nineteen transjugular or percu-
taneous liver biopsies were performed in 16 patients.
Blood transfusion was suspected to be responsible for hepatitis
if elevated ALT activity was detected between 2 and 26 weeks
after transfusion.
Serological studies
Serum samples were prospectively assayed for HBs Ag, anti-
HBs and anti-HBc (Abbott laboratories, North Chicago, Illinois,
USA). When hepatitis was suspected, samples were also tested for
antibody to hepatitis A virus by commercial assays (Abbott
Laboratories), antibody to cytomegalovirus and herpes virus by
enzyme immunoassay, and antibody to Epstein-Barr capsid and
nuclear antigen by immunofluorescence.
In all, 1772 selected samples corresponding to individual se-
quences from the 217 hemodialyzed patients were tested for HCV
by second-generation anti-HCV enzyme immunoassay (ELISA 2,
Ortho Diagnostic Systems, Raritan, New York, USA) at least
once a year in case of anti-HCV negativity, but every month and
even every week in case of anti-HCV positivity. A recombinant
immunoblot assay (RIBA 2, Chiron Corporation, Emeryville,
California, USA) was repeatedly used for samples positive by
ELISA. The RIBA 2 assay uses four HCV antigens comprising the
c22-3 core protein and the three non-structural proteins c33c,
clOO-3 and 5-1-1. Samples reactive to at least two HCV antigen
bands were considered RIBA positive, and samples reactive to
only one band were considered indeterminate. In the absence of
reactivity they were considered negative. Samples reactive by
ELISA but negative by RIBA were considered anti-HCV nega-
tive.
Additional fresh sera from 23 anti-HCV patients, one of whom
lost his anti-HCV positivity, were analyzed for HCV RNA after
PCR amplification. PCR was performed according to the protocol
previously described [7], on recent fresh samples which were
immediately separated from the clot using recommended proce-
dures to avoid contamination. Southern blots were considered
positive if they had the same apparent molecular weight as the
positive control.
Epidemiological analysis
The annual incidence of HCV was taken as the ratio of the
number of new seroconversions to HCV diagnosed each year to
the number of person-years of exposure to the risk of HCV. The
cumulative incidence was then calculated. Comparisons between
groups were made by the chi-square method.
Results
Definition and frequency of events
HCV infection affected 86 of the 217 patients tested (39.6%), as
evidenced by repeated anti-HCV ELISA positivity (Fig. 1); 84 of
86 cases (97.5%) were confirmed by a positive RIBA and 2 of 86
were indeterminate.
Forty-one of these patients had anti-HCV antibodies present at
entry in the unit. Thirty-four of them (83%) had been previously
dialyzed in another unit and were positive for anti-HCV at
transfer. The seven others were positive prior to initiation of
dialysis; 4 of 7 came from North Africa, giving an infection rate of
21% for this geographic subgroup versus 1.5% for the others.
The other 45 patients, who were negative prior to initiation of
dialysis and seroconverted during the course of chronic dialysis,
developed primary HCV infection; 29 of 45 had a history of blood
transfusion (64.5%) prior to conversion, 5 of 45 may have had
other parenteral exposures, 4 of 45, all of whom were dialyzed on
the same machine with closed circulation of dialysate, serocon-
verted to HCV within a two month period, and seven patients had
no obvious risk factors.
Clinical and serological fratures of hepatitis C
Sixty-seven patients were shown to have non-A, non-B hepati-
tis. Of these, 61(91%) ultimately proved to have antibodies to
HCV; they included 45 patients with primary HCV infection and
19 previously infected patients (Fig. 1).
The features of primary HCV infection were studied in 42 of
the 45 patients who seroconverted to HCV during the course of
chronic dialysis, since two of them had too short a follow-up and
one seroconverted in the absence of hepatitis. The mean age of
these patients (Table 1) was 50 years (range 26 to 77 years); 22
(5 1%) were male; their initial nephropathy was not different from
that of the other groups. The mean interval between the initial
dialysis and the development of hepatitis was 41.2 months (range
1 to 147 months). The course of hepatitis C was not different in
the post-transfusion cases, and in those in which it was probably
acquired in the dialysis setting.
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Table 1. Clinical history in relation to HCV status for 217
hemodialyzed patients
Anti-HCV antibodies
Positive
Seroconversion Previous HCV
Characteristics to HCV infection Negative
Number of patients 45 41 131
Mean age years 50 46 51
Sex
Male 24 23 62
Female 21 18 69
Ethnic groups
North Africa 6 5 8
Others 39 36 123
Mean duration of 85,9 118.8 70.8
hemodialysis
months
Non-A, non-B 42 (62.7%) 19 (28.4%) 6 (8.9%)
hepatitis
Max mean ALT 357 143 309
lU/liter
Abbreviation is: ALT, alanine aminotransferase.
The acute phase of the disease was mild in 7 patients and
marked in the 35 others. Icterus or subicterus was present in 6
(14.3%). The pattern of ALT activity which revealed acute
primary hepatitis C was variable. In the 7 mild cases (16.7%),
hepatitis began by low fluctuating levels of ALT activity followed
by a single peak which was delayed and moderate. The other
patients exhibited one, two or three successive ALT peaks, usually
at lower levels, separated by normal or abnormal ALT levels; the
mean maximum ALT level was 357 lU/liter. In all the patients,
hepatitis followed a chronic course, because elevated or fluctuat-
ing ALT values always lasted more than six months (range 6.25
months to 7 years).
In these cases of HCV seroconversion combined with hepatitis,
the first samples positive by ELISA were negative, indeterminate
and positive by RIBA in 2, 27 and 13 patients, respectively (5, 64
and 31%). RIBA 2 reactivity never preceded ELISA positivity,
and sometimes remained indeterminate for periods ranging from
one week to four years after seroconversion. Three temporal
patterns could be distinguished: 21 patients (50%) had detectable
ELISA positivity together with abnormal ALT in the same
sample, but markedly elevated values were only found in 12 of
them. In six other patients (14.3%), ELISA positivity preceded
the first ALT increase by 0.5 to 1.5 months, whereas in the
remaining 15 (35.7%) it only occurred one week to five months
after the onset of hepatitis (mean 6 weeks).
The remaining 19 patients with pre-existing chronic hepatitis C
also had biochemical hepatitis that resembled that observed in
primary HCV infection, but at lower levels and with more
frequent ALT fluctuations. All of them were clearly anti-HCV
positive by RIBA.
Long-term follow-up study and outcome ofHCV infection
Seventy-eight of the 86 patients (9 1%) who were followed for at
least a year after anti-HCV detection (median 5 years) were
included in this study (Figs. 2 and 3). After its appearance,
anti-HCV persisted for years. Only eight patients became negative
or indeterminate for anti-HCV antibodies on repeated RIBA
testing. Furthermore, when fresh sera were tested for HCV RNA
after PCR amplification, 19 of 22 anti-HCV positive patients
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Fig. 1. Clinical and serological expression of HCV infection: a 12-year follow-up of 86 hemodialyzed patients. *Two patients were excluded because of a
too short follow-up period after seroconversion.
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(82.6%) had a positive assay, whereas the one patient who had lost
anti-HCV antibodies was negative.
While most patients did not have ALT activity characteristic of
liver disease, 16 patients underwent 19 liver biopsies. Eight liver
biopsies, performed within two years of infection onset, revealed
discrete portal fibrosis or minimal changes in 6 cases, and chronic
active hepatitis with cirrhosis in 2 alcoholic patients. The 11 other
biopsies, performed between 3 and 13 years after anti-HCV
detection, showed chronic active hepatitis in 6 patients, with
cirrhosis in one and hepatocellular carcinoma in another after 9
and 11 years, respectively. The 2 patients who had iterative
biopsies (2 and 3, respectively) evolved from discrete portal
fibrosis to chronic active hepatitis six and seven years later.
After combining the overall data for 393 person-years of
follow-up, we identified three distinct patterns for predicting the
severity and infectiousness of the disease which developed in our
dialysis patients (Figs. 2 and 3). The first pattern, which was very
common (69.2%) correlated with the most severe and infectious
form of the disease (Fig. 3). It applied to 54patients who retained
ALT and/or GGT changes: out of these 54 patients, 24 (30.8%)
had either elevated or fluctuating ALT levels (Fig. 2, case 1), but
the remaining 30 (38.4%) had normal ALT activity for two to
seven years. Regardless of the ALT activity profile, all 54 patients
exhibited serially elevated GGT activity (Fig. 2, cases 3 and 4) and
confirmed RIBA in all but one case. Furthermore, this group
included (Fig. 3) the 8 patients with histologically active hepatitis,
and the one with hepatocellular carcinoma. In addition, 14 of 14
of the patients tested were positive for HCV RNA. The second
less common pattern (Fig. 3) included 16 patients (20.5%) with
entirely normal ALT and GOT activity but persistently elevated
anti-HCV titers with or without positive HCV RNA. These
features should be compatible, either with a healthy chronic
carrier state or with an intermediary phase preceding eventually
transient clearance and the reduction of HCV infection, as
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Fig. 2. Biochemical and serological markers of HCV infection. Abbreviations are: NALT, normal alamine aminotransferase (ALT) activity; COV, ELISA
cut off value; LB, liver biopsy; NGGT, normal gamma glutamyl transpeptidase (GGT) activity; CAH, chronic active hepatitis; CAH-C, CAH with
cirrhosis.
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Table 2. Prevalence, incidence and cumulative risk of HCV infection (Januaiy 1, 1980—January 1, 1992)
Year
Annual prevalencea
N (%)
Person-years"
PA1 = (N, + N.÷1/2)
Person-years
at riskC
Annual Cumulative incidencee
incidence"
% Years % Years %
1980 29/77 (37.7) 70 45 8.8 1
1981 41/94 (43.6) 78.5 45.5 17.5
1982 41/97 (42.2) 86 48 6.25
1983 42/100 (42.0) 90 54 11.1 54
1984 45/109 (41.2) 93 52 7.6
1985 41/104 (39.4) 92 57 10.5
1986 43/106 (40.5) 91 54 11.1 58
1987 40/105 (38.0) 90.5 53.5 5.6
1988 38/100 (38.0) 85 47 0
1989 39/106 (36.8) 82.5 46.5 6.4 9.9
1990 31/96 (32.2) 86 57 3.5
1991 26/89 (29.2) 76 50 0
a Prevalence relates the total number of anti-HCV seropositive patients to the population tested
bOne half the total number of patients present at the beginning and end of the period
C Same method as b but reduced to the calculated number of anti-HCV seronegative patients
Relates the total number of seroconversions detected within a year to the total number of person-years at risk
A calculation expressed by 1 — Exp — ( of annual incidence)
reflected by the loss of RIBA bands. The third pattern (Fig. 3)
which included 8 patients was rare (10.3%). It seemed to correlate
with resolutive hepatitis, as suggested by the combination of
normal enzymatic activity with either complete clearance of HCV
markers (Fig. 2, case 2) or gradual loss of RIBA bands and
undetectable HCV RNA.
Natural epidemiologic history of HCV infection
From the early 1980's to January 1992, the prevalence and
especially the incidence and cumulative risk of HCV infection
clearly varied (Table 2). The rate of new infections decreased
significantly after 1988 to 1990, when routine testing of the blood
supply for surrogate markers (ALT and anti-HBc, 1988) and HCV
antibodies (March 1990) were implemented in France. However,
although seroconversion to HCV became nil in 1988 and 1991, we
still identified one additional post-transfusion case in 1989, and
more especially 4 cases of hepatitis C were certainly acquired in
our dialysis setting in 1989 and 1990. On the other hand, even
though the prevalence also decreased, its rate was still very high at
the end of the study (29.2%).
The study of seroconversion versus time (Fig. 4) shows that in
1980, the first year of the study, seroconversion to HCV only
occurred in patients who had a history of blood transfusion. This
figure also shows that the consecutive yearly incidence of trans-
fusion-associated HCV infection was variable and dropped over
time, whereas that of nosocomial dialysis HCV infection re-
mained relatively constant at 1.9% to 4.3% (ito 2 cases per year),
except for the peak in 1981.
Residual hepatitis
Six of the 67 patients who had non-A, non-B hepatitis (9%)
lacked HCV markers and were therefore classified as having
10%
8%
6%
4%
2%
0%
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Fig. 4. Distribution of HCV seroconversion
versus time. Symbols are: (—A—) nosocomial
incidence; (—s—) post-transfusion incidence.
non-A, non-B, non-C hepatitis. Hepatitis was mild in these six
cases; its duration varied from one to four months in four patients
and exceeded six months in two, Two of these six patients (33.3%)
were immigrants from North Africa, and only three (50%) had a
history of blood transfusion. In addition, 18 of the 131 HCV-
negative patients had ALT fluctuations without meeting hepatitis
criteria. By contrast, 107 of our patients without detectable HCV
infection (81.7%) had constantly normal ALT and GGT activity in
their follow-up samples.
Discussion
This prospective study of 217 hemodialyzed patients over a
period of up to 12 years shows that HCV infection was very
frequent in our dialysis population (39.6%), that virus C was
responsible for 91% of non-A, non-B hepatitis cases and that
hepatitis mostly revealed the primary HCV infection (42 of 43).
In the present study which began in 1980, diagnosis of HCV
infection raised many doubts until the introduction of specific
anti-HCV assays in 1989, because the ALT changes were even
milder than those reported in nonimmunocompromised popula-
tions [2, 3, 8]. When specific anti-HCV testing became available,
the results remarkably corroborated these enzymatic changes,
even when they were minimal. The HCV infection was therefore
clear, as evidenced by a positive ELISA (86 of 86) with either a
positive RIBA (84 of 86) or an indeterminate RIBA (2 of 86).
However, our results underlined the difficulties of early diagnosis
of primary HCV infection in hemodialyzed patients, including the
identification of atypical seroconversion profiles such as slight,
fluctuating or non-existent changes in ALT activity, delayed
detection of anti-HCV, and long-term persistence of an isolated
indeterminate RIBA preceding RIBA positivity.
The chronic course of hepatitis was most difficult to recognize,
because elevated ALT activity was often interrupted by long
periods of normal activity. This means that after the onset of
hepatitis, the follow-up of HCV infection must be extremely
meticulous and very prolonged. Using this approach, hepatitis had
a chronic course in all our patients who seroconverted, and this
frequency was higher than that reported in nonimmunocompro-
mised populations [2, 3, 8—10].
Rapid progression of the liver disease was only observed in two
patients with chronic alcoholism, as already reported [11]. By
contrast, the long-term progression of the disease was more
complex to define. The severity of HCV infection was not simply
based on the ALT changes, which did not prove to be a reliable
long-term marker of the disease, because patients with normal
ALT activity had histologically active hepatitis. Importantly, all of
them exhibited chronic GGT increase. Therefore, in our experi-
ence, GGT activity, which remained serially elevated long after
the ALT level returned to normal, emerged as a pertinent marker
for predicting the long-term severity of HCV infection.
The overall incidence and prevalence of HCV infection varies
widely among dialysis units all over the world [12—16]. This
variation is likely due to multiple factors, including the care with
which one attempts to identify cases, as well as the past transfu-
sion practices of the unit. Although there were no data given
regarding the transfusion history of the patients who transferred
from other dialysis facilities, we identified two main distinct forms
of HCV infection in our unit. Most of our patients derived their
infection from transfusion with contaminated blood (64.5%).
Historically, blood transfusion was the first identified source of
HCV contamination, because the patients contaminated during
the first year of the study were only those who had a history of
blood transfusion and there were no cases of infection derived
from other sources.
As recently reported [17], it soon became evident that other
risks of HCV infection existed in the dialysis setting. Thus, four
patients who shared the same dialysis machine with closed
circulation of dialysate seroconverted within a two month period.
However, it was impossible to assert that any specific source was
responsible for the spread in this outbreak, since multiple com-
bined risk factors do exist in dialysis units, either from contami-
nated machines and/or from any other dialysis equipment and
from the overall patient setting.
Finally, the sources of infection remained unknown for seven of
our patients, for whom other causes of HCV spread could not be
excluded [18—20]. HCV infection was already present prior to
initiation of dialysis in seven of the 86 anti-HCV positive patients.
This underlines the importance of starting HCV detection early in
the management of kidney disease [21].
As previously published [22, 23], the decrease observed in the
incidence of HCV since blood screening was started is encourag-
ing. Combination of this screening with the recent reduction in the
number of blood transfusion in our unit following the use of
erythropoietin (1988) was associated with a drastic drop in the
1980 81 82 83 84 85 86 87 88 89 90 91
Time, year
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number of post-transfusion cases. We hope that we have suc-
ceeded in eradicating this source of HCV from our dialysis unit, as
no new cases have been detected since 1989. However, other types
of HCV infection acquired in the dialysis setting do remain, as
evidenced by the detection of four new cases, two in 1989 and two
in 1990. Despite its low incidence (ito 2 new cases per year), this
nosocomial infection must not be underestimated. It was only
during the last year of the study (1992) that we failed to observe
any new infection from any source. However, this does not mean
that dialysis hepatitis has been eradicated, since anti-HCV posi-
tive patients should be considered infectious [24—28] unless one
can document long-term clearance of HCV RNA. Thus, most of
the present cases of this study were associated with evidence of
chronic HCV infection. Since anti-HCV antibodies persisted for
years, the yearly prevalence of HCV infection tended to decrease
over time, but its rate was 29.2% at the end of our study. This
means that there is still a permanent risk of HCV spread in the
dialysis setting. Consequently, we should recommend rigorous
enforcement of multiple basic measures. These prophylactic mea-
sures should include the removal of dialysis machines with closed
circulation of dialysate, the universal use of disposable materials
and of efficacious disinfectants, the rigorous cleaning of each
patient setting between dialysis sessions, and the reinforcement of
meticulous health care precautions.
Since the effects of immunoprophylaxis have not yet been
clearly defined [29, 30], the current tracking of HCV infection
should be encouraged together with the extension of such non-
specific prophylactic methods until a vaccine becomes available.
These measures, combined with the treatment of the chronic and
even acute phases of the disease [31, 32] should reduce the rate of
HCV infection in dialysis units. By contrast, if HCV infection
persists despite these efforts, even at a low rate, the development
of distinct units will have to be considered to avoid contaminating
additional hemodialyzed patients.
In conclusion, HCV was responsible for 91% of dialysis-
associated non-A, non-B hepatitis cases among our hemodialyzed
patients. HCV infection in these patients was chronic in nearly
90% of cases. Transmission of HCV infection in the dialysis
setting was both transfusional and nosocomial. HCV prophylaxis
should now focus on the eradication of nosocomial infection,
which in the absence of specific prophylaxis will require very
meticulous precautions.
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